Capital Markets Update / State of the Economy

Keith Gaub

Vice President & Assistant Treasurer
Bristol Myers Squibb

Mr. Gaub oversees Capital Markets, Financial Risk Management, International Treasury & International Treasury Operations, Cash Leadership and Benefit Investments.  Prior to joining BMS, he worked at Zoetis for nine years, most recently serving as Senior Director of Investor Relations, where he managed relationships with sell-side analysts and large institutional investors, in addition to supporting their CEO and CFO during earnings announcements.

Courtney Rickert McCaffrey

Global Insights Leader
EY Geostrategic Business Group

Ms. McCaffrey drives market-leading insight around geopolitics, corporate performance and political risk management. She leads the analysis of the annual EY Geostrategic Outlook and advises clients on how geopolitical developments may impact their companies’ operations and strategies, and how to manage political risks more proactively. She is also the co-author of a forthcoming book entitled Geostrategy by Design: How to Manage Geopolitical Risk in the New Era of Globalization.

Patrick Morley

Senior Managing Director Equity Capital Markets
Leerink Partners

Mr. Morley is a Senior Managing Director in Leerink Partners’ Equity Capital Markets group, advising private and public healthcare companies on the optimal strategy and tactics to achieve their financing goals. He joined the Firm in 2011 as a member of the Healthcare Investment Banking group before transitioning to his current role. 

Philip Sclafani

Partner
PWC

Mr. Sclafani has deep experience supporting branded, biotech, generics, medical device and other healthcare companies. He leads high performing teams to address his clients most challenging issues across strategy, operations, digital & analytics, compliance and technology in the Pharma commercial organization, medical affairs, M&A / business development and other key functions.

Roel van den Akker

Pharmaceutical and Life Sciences Deals Leader
PWC

Mr. van den Akker is PwC’s Pharmaceutical and Life Sciences Deals Leader, with vast experience in transactions, deals, M&A and divestitures. He leads a team focused on helping pharma, life sciences and med tech companies win through deals and seamlessly capture value during acquisitions.

MODERATOR: Scott Megaffin

President & CEO
Adiso Therapeutics

Leveraging his extensive experience as a biopharma senior executive, Mr. Megaffin has guided both public and private companies as CEO and Board Director. His deep knowledge spans a broad range of therapeutic areas, including immunology, inflammation, oncology, anti-infectives, pain, critical care and virology. He currently applies his expertise beyond Adiso by serving on the board of BioNJ and Adastra.